Let's bring in Charlie Babrinskcoy. He's the vice chair of Aerial Investments. Charlie, it's great to see you again.Welcome. >> Thank you. Welcome back, Kelly.Great to see you. >> Thank you. And I you I one of my most memorable things right before I I think I I went out was that you had said to everybody, be careful with Oracle here.Think twice before getting involved. And that was maybe I don't know 30 40% from where we are now. So what what do you do with the stock now.Yeah, I think my exact words were tr ...

Fannie Mae and Freddie Mac have added billions of dollars of mortgage backed securities and home loans to their balance sheets in recent months. That's adding to speculation. They're trying to lower lending rates and boost profitability ahead of a potential secondary offering.Bloomberg's Scott Carpenter covers credit and joins us here on set. Scott, great to have you on, on the program. This is a story that has been persistent because Bill Ackman often tweets about Fannie and Freddie.The president and those ...

Core Insights - Exxon Mobil Corporation (XOM) announced its 2030 corporate forecast, projecting significant earnings and cash flow growth, which positively impacted its share price by 3.07% to $119.54 [1] Financial Projections - By 2030, XOM anticipates $25 billion in earnings growth and a $35 billion increase in cash flow, both up $5 billion from previous estimates, achieved without increasing spending [2] - The upstream segment is expected to contribute over $14 billion in earnings growth, while the Product Solutions business is projected to exceed $9 billion [2] - XOM expects a return on capital employed of more than 17%, indicating strong operational efficiency and profitability, with a projected cumulative cash flow generation of $145 billion by 2030, assuming a Brent oil price of $65 per barrel [3] Shareholder Value and Capital Management - XOM is on track with a $20 billion share repurchase program for this year, maintaining the same pace for the following year, which is expected to drive earnings growth of around 13% through 2030 [4] - The company has increased its annualized dividend per share for 43 consecutive years, reflecting a commitment to returning value to shareholders [4] Production Expectations - By 2030, XOM's daily oil production is projected to rise to 5.5 million barrels of oil equivalent, primarily driven by advancements in the Permian Basin, offshore Guyana, and its LNG portfolio [5] Strategic Focus - The company is shifting its focus towards more profitable business areas while reducing operational costs and enhancing financial stability, which is expected to add long-term value for shareholders [6]

Core Viewpoint - Cemtrex, Inc. is undergoing a multi-year transformation aimed at expanding operating income, improving margins, and building a scalable enterprise [1] Group 1: Acquisition Strategy - The company is in the final stages of closing the acquisition of Invocon, a Texas-based aerospace and defense engineering firm, which is expected to enhance technology capabilities and contribute positively to operating income starting in fiscal 2026 [2] - Cemtrex has signed a new letter of intent to acquire a Tennessee-based industrial services business, which will extend the geographic footprint of its Advanced Industrial Services segment and is expected to enhance long-term earnings power [4] - The company previously decided not to proceed with the acquisition of a robotics integration firm, emphasizing a disciplined approach to acquisitions focused on profitability [3] Group 2: Operational Focus - Cemtrex is prioritizing profitability across its operating segments, with a focus on profitable growth and strengthening its earnings base [5] - The Advanced Industrial Services segment is maintaining solid performance with recurring customer activity and is emphasizing higher-margin work and geographic expansion [7] - Vicon Industries, part of Cemtrex's Security segment, has begun shipping units of its NEXT product line, with a focus on improving margins and driving efficiency through software and AI-enabled offerings [7] Group 3: Future Outlook - The company plans to continue pursuing additional acquisitions that align with its strategy to expand earnings scale and enhance strategic capabilities [5] - Cemtrex is committed to building a more resilient and higher-margin business, laying a foundation for long-term shareholder value [5]

And a lot of times what what a lot of protocols will sort of tout as revenue or profitability is more so just a circular economy. With stocks there's earnings and and like there's profitability, right. There's like an earnings report.Like an investor can take a look at the earnings report, see the company's growing, and then be like, "Yeah, I want to keep putting my money into that." With crypto, we don't really have that, right. Like it's just speculation. It's just kind of liquidity flows from one project ...

Core Viewpoint - Sweetgreen faced significant challenges in 2025, leading to a 78% decline in stock value year-to-date, but there are indications that the company's difficulties may be temporary, presenting potential for recovery in 2026 [3]. Sales Performance - Same-store sales at Sweetgreen fell by 9.5% in the third quarter of 2025, highlighting the operational challenges the company is experiencing [6]. - Comparisons for same-store sales are expected to improve in 2026, as the company will be comparing against a year with positive sales [6]. Profitability Outlook - Sweetgreen's GAAP operating loss widened in 2025, and the company anticipates reporting an adjusted EBITDA loss after achieving profitability in 2024 [9]. - Management is taking steps to strengthen the balance sheet, including the sale of Spyce and scaling back on new store openings, planning for 15-20 net new stores in 2026 compared to 37 in 2025 [9]. Cost Management - The company needs to improve cost control to enhance profitability, especially if same-store sales do not grow significantly [10]. - The stock's significant decline may provide an opportunity for a rebound if the company can effectively manage costs and improve its economic model [10].

Core Insights - CVS Health's latest results indicate stable sales and adjusted profits, with upward adjustments to forecasts, but the stock is considered "cheap but risky" due to profit quality and high debt levels [2][15]. Financial Performance - In Q3 2025, CVS reported revenue of approximately $103 billion, an 8% increase year-over-year, with all segments contributing to growth [3]. - The adjusted EPS was around $1.60, a significant rise from the previous year, leading management to increase the full-year 2025 adjusted EPS forecast to the mid-$6 range [5]. - A $5.7 billion charge related to the Health Care Delivery segment resulted in a net loss for the quarter, affecting reported profit figures [4]. Valuation Metrics - CVS trades at a low Price-to-Sales (P/S) ratio of about 0.2x compared to roughly 3x for the S&P 500, indicating undervaluation [12]. - The Price-to-Earnings (P/E) ratio is over 200x, primarily due to one-time charges, but falls into low double digits when based on future projections or adjusted earnings [8][9]. Profitability and Debt Concerns - CVS has managed annual sales growth of about 7-8% over the past three years, slightly better than the S&P 500 average, but profitability is currently weak with low operating profit margins [10][13]. - The company's total debt is in the low $80 billion range, with a debt-to-equity ratio in the mid-80% range, indicating a high level of debt compared to market value [13][11]. Investment Suitability - The stock is deemed suitable for investors willing to take risks, as it is undervalued but has weak overall financial health due to high debt and low profit margins [15][16]. - CVS is not considered a safe investment, having experienced significant declines during market corrections in the past [14][17].

Core Viewpoint - Lands' End, Inc. reported mixed financial results for Q3 2026, with earnings per share slightly missing estimates, but showing strong operational performance and strategic growth potential in both B2B and consumer segments [2][3][4]. Financial Performance - Earnings per share (EPS) was $0.16, slightly below the estimated $0.17 [2][6]. - Revenue was approximately $317.5 million, significantly below the expected $466.4 million [2][6]. - The company achieved a 120 basis point increase in gross margin and a $5.8 million rise in net income [3][6]. - Adjusted EBITDA surged by 28%, indicating a focus on profitability and operational efficiency [3]. Strategic Direction - CEO Andrew McLean and CFO Bernard McCracken discussed the company's strategic direction during the earnings call [3]. - The partnership with Delta Air Lines highlights Lands' End's capabilities in integrating product, service, and technology for enterprise clients, showcasing long-term growth potential in the B2B segment [4]. Market Position and Financial Metrics - Lands' End is successfully reaching a younger and more diverse customer base, enhancing brand relevance [5]. - The company has a P/E ratio of 37.69 and a price-to-sales ratio of 0.34, indicating investor confidence [5]. - With a debt-to-equity ratio of 0.14 and a current ratio of 1.76, Lands' End maintains a strong financial position to support its growth strategy [5].

Core Insights - The investor reaction to Phreesia's third-quarter performance was overly negative despite the company showing significant improvements in revenue and profitability [1][8] Financial Performance - Phreesia reported a 13% year-over-year increase in revenue, exceeding $120 million, driven by a 7% growth in the average number of healthcare services clients to 4,520 [2][4] - The company achieved a net profit of nearly $4.3 million ($0.07 per share), a turnaround from a loss of $14.4 million in the same quarter last year, with both revenue and profit figures surpassing analyst expectations [4][5] Revenue Streams - All three revenue streams—subscription and related services, network solutions, and payment processing—grew at low double-digit rates of 12%, 14%, and 11% respectively during the quarter [5] Guidance and Market Reaction - Phreesia tightened its full-year 2026 revenue guidance to $479 million to $481 million, slightly below analyst expectations of nearly $486 million [6] - The company's forecast for non-GAAP EBITDA was raised to $99 million to $101 million, up from a previous range of $89 million to $92 million [7] - Despite the stock's significant drop of over 23% following the earnings release, the negative sentiment appears exaggerated, primarily due to the revenue guidance miss [1][8]

Core Insights - Phreesia, Inc. is a healthcare technology company focused on patient intake management, enhancing operational efficiency and patient engagement [1] - The company has a market capitalization of approximately $1.21 billion and has experienced significant stock price fluctuations over the past year [4] Financial Performance - Phreesia reported solid earnings with two consecutive quarters nearing breakeven, indicating progress towards profitability [3][5] - Despite the positive earnings report, the stock price declined by approximately 0.86%, fluctuating between $19.40 and $21.24 [2][5] Market Outlook - Canaccord Genuity set a price target of $33 for Phreesia, suggesting a potential increase of about 64% from its trading price of $20.12 [2][5] - The stock has seen a high of $32.76 and a low of $18.55 over the past year, reflecting volatility in the market [4]